Thromboembolism – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Thromboembolism – Pipeline Review, H2 2018’, provides an overview of the Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Thromboembolism

– The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects

– The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Thromboembolism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Thromboembolism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Johnson & Johnson

Portola Pharmaceuticals Inc

Tetherex Pharmaceuticals Corp

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thromboembolism Overview

Thromboembolism Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thromboembolism Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thromboembolism Companies Involved in Therapeutics Development

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Johnson & Johnson

Portola Pharmaceuticals Inc

Tetherex Pharmaceuticals Corp

Verseon Corp

Thromboembolism Drug Profiles

antithrombin III (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1213790 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betrixaban Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GCC-2107 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-9375 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysimab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Thromboembolism Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivaroxaban Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SelK-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAP-ANV Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-1902 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YG-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thromboembolism Dormant Projects

Thromboembolism Discontinued Products

Thromboembolism Product Development Milestones

Featured News & Press Releases

Jun 14, 2018: Verseon to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagulant with Reduced Bleeding Risk

Jun 07, 2018: Verseon presents new data on its precision oral anticoagulants at BIO International Convention 2018

May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018

Mar 23, 2018: Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

Feb 20, 2018: Portola Pharmaceuticals Announces Results of CHMP Oral Explanation for Betrixaban

Dec 19, 2017: FDA Approves Prior Approval Supplement for Commercial Launch of Portola Pharma's Novel Oral Anticoagulant Bevyxxa (betrixaban)

Dec 13, 2017: Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Betrixaban at the 59th American Society of Hematology (ASH) Annual Meeting

Nov 21, 2017: Portola Pharmaceuticals Provides Update on Bevyxxa (betrixaban) Commercial Launch

Nov 07, 2017: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association Scientific Sessions 2017

Nov 01, 2017: Janssen to Present Abstracts on XARELTO at ASH 2017

Oct 30, 2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism

Sep 15, 2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thromboembolism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Thromboembolism Pipeline by Bayer AG, H2 2018

Thromboembolism Pipeline by China Biologic Products Inc, H2 2018

Thromboembolism Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Thromboembolism Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Thromboembolism Pipeline by GC Pharma, H2 2018

Thromboembolism Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Thromboembolism Pipeline by Johnson & Johnson, H2 2018

Thromboembolism Pipeline by Portola Pharmaceuticals Inc, H2 2018

Thromboembolism Pipeline by Tetherex Pharmaceuticals Corp, H2 2018

Thromboembolism Pipeline by Verseon Corp, H2 2018

Thromboembolism Dormant Projects, H2 2018

Thromboembolism Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Thromboembolism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports